iRhythm Q2 revenue up 26.1% to $186.7M; net loss narrows to $14.2M; raises FY 2025 guidance

iRhythm Holdings, Inc.

2025-Q2 EPS reported -$1.41 revenue$345,364,000

Revenue $186.7M (+26.1% YoY); gross margin 71.2% (+130 bps).
Net loss $14.2M ($0.44/sh) improved from $20.1M loss ($0.65/sh) in Q2 2024.
Adjusted net loss $10.2M ($0.32/sh) improved from $18.8M loss ($0.61/sh) YoY.
FY 2025 guidance raised: revenue $720M-$730M; adj. EBITDA margin 8.0%-8.5%.
Unrestricted cash $545.5M; partnership with Lucem Health for AI-driven early disease detection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.